Is Teladoc a top competitor to Doximity?

What To Expect From Teladoc’s Earnings

Teladoc’s price gained significantly from the pandemic, but as people return to in-person consultations, what can we expect from its earnings?

During the pandemic, Teladoc’s (NYSE: TDOC) virtual consultation services were extremely popular with customers looking to avoid catching the virus in hospitals and medical centers. 

While the digital era is disrupting many industries, after a health emergency there’s nothing quite like an in-person chat with a doctor to settle the nerves. Therefore, investors are hoping that Teladoc’s services have stayed popular as people return to physical doctor appointments and check-ups. 

Teladoc needs to reassure its shareholders that its services are here to stay — pandemic or no pandemic. With Teladoc shares down over 25% year-to-date, the company’s report will be scrutinized. Let’s take a look at what to expect from Teladoc’s earnings. 

When is Teladoc’s earnings date?

Teladoc reports earnings for the second quarter of 2021 on Tuesday, July 27 at 5:00 PM Eastern Time. 

How can I listen to Teladoc’s earnings call?

To listen to the call and to access the transcript, as well as the shareholder’s letter and the financial statements for the quarter, all you need to do is go to Teladoc’s investor relations page

What to expect from Teladoc’s earnings

Wall Street expects Teladoc to post a second-quarter loss of $0.59 per share, up from its loss of $0.34 in the year-ago quarter. Analysts estimate Teladoc’s sales to hit $500.97 million for Q2, representing a 107% jump from the year-ago quarter. 

Despite the hyper-growth Teladoc experienced this time last year, the company is still expecting revenue to hit $1.97 billion in 2021, up 80% year-over-year (YoY). The company is also predicting total visits for the second quarter to reach between 3.2 to 3.4 million, a 19.8% rise YoY. 

The telemedicine and virtual healthcare company expects total paid membership to bring in up to 54 million members, a 2.9% jump from the previous quarter. 

Demand for Teladoc services will likely cool off from pandemic highs and investors should not be surprised to see this fact resonate in the company’s financials. However, the spreading of the Delta variant might be good news for Teladoc as people are likely going to request virtual consultations once more instead of risking a physical trip to the doctors. 

This disruptive stock is set to revolutionize the healthcare industry but if it reports another disappointing earnings statement, investors might inject their money elsewhere. 

If you want to stay ahead of the curve and invest in growing industries like healthcare, MyWallSt’s got you covered with a shortlist of market-beating stocks, so you too can accumulate long-term wealth. Simply click here for a free trial today. 


MyWallSt operates a full disclosure policy. MyWallSt staff currently holds long positions in companies mentioned above. Read our full disclosure policy here